Results 121 to 130 of about 2,458 (200)

Integrative machine learning-guided <i>in silico</i> and <i>in vitro</i> approach reveals selective small molecule inhibitors targeting mutant IDH1. [PDF]

RSC Adv
Bajaj M, Kumar R, Pandey V, Parvez S, Tanneru HK, Aparoy P, Karnati R.   +6 more
europepmc   +1 more source

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia [PDF]

, 2017
C. J. Owen, C. L. Toze, C. Shustik, I. Bence-Bruckler, R. Delage, S. Coutre   +5 more
core   +1 more source

Targeting PI3Kδ in cancer: a setback or the end. [PDF]

Front Oncol
Hao Z, Arnold S, Kolesar J.
europepmc   +1 more source

A long-lasting PI3Kδ inhibitor zandelisib forms a water-shielded hydrogen bond with p110δ and demonstrates sustained inhibitory effects. [PDF]

Am J Cancer Res
Kunieda K, Nagiri C, Watanabe M, Yoshida T, Zou J, Kaneda A, Takahashi Y, Aburai K, Saito JI, Umehara H, Otsu Y, Ishii T.   +11 more
europepmc   +1 more source

P1123: TEMPO: A PHASE 2, RANDOMIZED, OPEN-LABEL, 2-ARM STUDY COMPARING TWO INTERMITTENT DOSING SCHEDULES OF DUVELISIB IN SUBJECTS WITH INDOLENT NON-HODGKIN LYMPHOMA (INHL)

HemaSphere, 2022
V. Vorobyev, D. H. Yoon, M. Kaźmierczak, S. Grosicki, C. Tarella, A. Genua, J. S. Kim, D. Cohan, M. Daugherty, I. W. Flinn, P. L. Zinzani, L. I. Gordon   +11 more
doaj   +1 more source

Lessons learned from experience of phosphatidylinositol 3-kinase inhibitors in chronic lymphocytic leukemia and lymphoma. [PDF]

Haematologica
Ghione P, Zinzani PL, Brown JR.
europepmc   +1 more source

Drug repositioning pipeline integrating community analysis in drug-drug similarity networks and automated ATC community labeling to foster molecular docking analysis. [PDF]

Front Bioinform
Colibăşanu D, Groza V, Occhiuzzi MA, Grande F, Udrescu M, Udrescu L.   +5 more
europepmc   +1 more source

Fluorescent properties of FDA-approved anti-leukemia drugs. [PDF]

Biomed Opt Express
Bereczki D, Haffaressas IL, Szabó Z, Tóth S, Füredi A, Fürjes P.   +5 more
europepmc   +1 more source

Quadshot Radiotherapy as Bridging Therapy for Adult Lymphoma Patients: A Single-Institutional Experience. [PDF]

Adv Radiat Oncol
Zeng J, Ng A, Smith A, Crombie JL, Patel CG.   +4 more
europepmc   +1 more source

Activated PI3 Kinase Delta Syndrome: Molecular Pathogenesis and Emerging Therapeutics. [PDF]

Cureus
Alraqibah EA.
europepmc   +1 more source